Fenwick & West represented Stoke Therapeutics, Inc. in the transaction. Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the...
You must be a Standard 1 Year member to access this content.
Fenwick & West represented Day One Biopharmaceuticals in the transaction. Day One Biopharmaceuticals (Nasdaq: DAWN) (“Day One”), a commercial-stage biopharmaceutical company announced its exclusive licensing agreement...
You must be a Standard 1 Year member to access this content.
Fenwick represented Sutro Biopharma on the deal. Sutro Biopharma (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), announced its option grant...
You must be a Standard 1 Year member to access this content.
Fenwick represented Sutro Biopharma, Inc. on the deal. Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage oncology company, announced its strategic collaboration and licensing agreement with Astellas Pharma...
You must be a Standard 1 Year member to access this content.
Fenwick & West LLP advised Day One Biopharmaceuticals on the deal. Day One Biopharmaceuticals, a clinical-stage biopharmaceutical company focused on accelerating new targeted therapies for children...
You must be a Standard 1 Year member to access this content.
